Key Questions for Legislators on the Institute for Clinical and Economic Review (ICER)

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

As states continue to grapple with prescription drug costs, a new Pioneer Institute study lays out the key ethical, methodological and disease-specific questions policy makers should address before deciding whether to contract with the Institute for Clinical and Economic Review (ICER) to conduct cost effectiveness reviews used to make decisions about the purchase of medicines and other medical innovations.

Download Report: Key Questions for Legislators on the Institute for Clinical and Economic Review (ICER)